Retinal Vein Occlusion Clinical Trial
Official title:
Special Drug Use Investigation of EYLEA for CRVO
This is a prospective, non-interventional, multi center post-authorization safety study that
includes patients with a diagnosis of CRVO. The investigator will have made the choice of
treatment (EYLEA) as well as the decision to use EYLEA according the Japanese Package Insert
prior to enrolling the patient in this study.
The observation period for each patient starts when therapy with EYLEA is initiated. The
enrollment period is 2 years. Patients will be followed for a time period of 2 years or until
it is no longer possible (e.g. lost to follow-up) within the 2 years.
For each patient, data are collected as defined in the case report form at the initial visit,
follow-up visits and final visit, either by routine clinical visits (as per investigators
routine practice).
There will interim analysis of study data: 6 months after last patient first visit and
J-PSUR(Japanese-Periodic Safety Update Report )
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06262737 -
Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
|
||
| Completed |
NCT04592419 -
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
|
Phase 3 | |
| Recruiting |
NCT05133791 -
NIR Fluorescence Molecular Imaging of ANXV-800CW in RVO Patients
|
Phase 1 | |
| Withdrawn |
NCT04011358 -
Retinal Vein Occlusion and Obstructive Sleep Apnea: A Case Control Study
|
N/A | |
| Completed |
NCT02898480 -
Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning
|
N/A | |
| Recruiting |
NCT01581151 -
Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
|
N/A | |
| Completed |
NCT01428388 -
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
|
N/A | |
| Completed |
NCT00970957 -
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
|
Phase 3 | |
| Recruiting |
NCT04075695 -
Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion
|
||
| Recruiting |
NCT03525132 -
Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)
|
N/A | |
| Recruiting |
NCT03762226 -
Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study
|
||
| Recruiting |
NCT02257333 -
Retinal Thrombosis and Atherosclerosis
|
||
| Recruiting |
NCT04140448 -
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
|
||
| Active, not recruiting |
NCT05003258 -
Functional and Anatomical Outcomes of Dexamethasone Intra-vitreal Implant in Patients With Resistant Macular Edema Secondary to Retinal Vein Occlusion After Intravitreal Anti-VEGF Injection
|
N/A | |
| Terminated |
NCT04707625 -
Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
|
Phase 4 | |
| Recruiting |
NCT04142164 -
Computer-based Tutorial and Automated Speech Recognition for Intravitreal Drug Injections
|
N/A | |
| Completed |
NCT02523339 -
Study of Retinal Oxygenation in Central Retinal Vein Occlusion
|
||
| Active, not recruiting |
NCT01449682 -
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
|
Phase 3 | |
| Completed |
NCT01568021 -
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
|
N/A | |
| Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 |